Phaseline

Companies › Peel Therapeutics

Peel Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PEEL-224–Phase 1Advanced Solid Tumor; Sarcoma; Refractory Solid Tumors–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05329103PEEL-224Phase 1Advanced Solid TumorOncologyOct 2026
NCT06709495PEEL-224Phase 1SarcomaOncologyNov 2028
NCT06721689PEEL-224Phase 1Refractory Solid TumorsOncologyApr 2030

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.